Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A

Reciprocal shareholding ratios: N/A

Name of mass media: Press release by the Shihlin District Prosecutors Office, Taiwan

Content reported: On January 9, 2017, the press release by Shihlin District Prosecutors Office stated that “Michael Chang (Chairman), Shue Youe-Kong (Ex-vice chairman), Amy Huang (General Manager), Yu Cheng-Der (Chief Scientific Officer), and Liao Jon-Jih (Director of Business Medical Advisor) are prosecuted due to the violation of the Stock Exchange Act. Michael Chang (Chairman) is also suspected to be in violation of the Anti-corruption Act.”

Cause of occurrence: Press release by the Shihlin District Prosecutors Office, Taiwan

Countermeasures: OBI firmly believes in the innocence of the management team. Defendants have hired defense attorneys to handle the legal process.

Any other matters that need to be specified: The operation and financial status of the company remain normal and unaffected. New drug development is a long journey associated with high cost. It is not a guaranteed success, which may increase the risk of investment. Investors shall make prudent judgments and investments.